Market Cap 20.62B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 8.74
Forward PE 8.82
Profit Margin 16.87%
Debt to Equity Ratio 0.36
Volume 1,561,800
Avg Vol 1,419,410
Day's Range N/A - N/A
Shares Out 146.62M
Stochastic %K 67%
Beta 0.11
Analysts Sell
Price Target $170.24

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
StockAutoPro
StockAutoPro Sep. 7 at 11:45 PM
$BIIB: Buy target $138.67 Sell target $147.7 Potential growth seen in biotech sector due to increased investment in Alzheimer's research.
0 · Reply
forprofit12
forprofit12 Sep. 5 at 4:39 PM
$BIIB what a miserable PoS stock. Nothing moves this POS.
0 · Reply
iQuicky
iQuicky Sep. 5 at 1:12 PM
$BIIB good news coming?
0 · Reply
StockAutoPro
StockAutoPro Sep. 4 at 2:39 PM
$BIIB: Buy target $137.89 Sell target $146.88 Robust drug pipeline could signal potential growth for this leading biotech firm.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 4 at 11:17 AM
$CCCC $BIIB C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA
0 · Reply
JarvisFlow
JarvisFlow Sep. 4 at 10:30 AM
Needham has adjusted their stance on Biogen ( $BIIB ), setting the rating to Hold.
0 · Reply
Chingying
Chingying Sep. 3 at 6:57 PM
$BIIB This will be a big game changer if Rolling submission on fast track for once weekly subcutaneous Leqembi IQLIK autoinjector wins FDA approval to treat AZ disease from the start at home. IQLIK just won approval as maintenance dose on 08/29/2025.
1 · Reply
scientificway
scientificway Sep. 3 at 3:41 PM
$BIIB strong buy. PMN, Have cash and good result. Should be 0.5-14 turn 1000 to 2000
0 · Reply
iQuicky
iQuicky Sep. 3 at 1:55 PM
$BIIB what’s going on?
0 · Reply
GuruLulu
GuruLulu Sep. 3 at 1:51 PM
$BIIB very nice
0 · Reply
Latest News on BIIB
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 2:24 PM EDT - 5 weeks ago

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript


Biogen to invest $2 billion more in North Carolina

Jul 21, 2025, 7:41 AM EDT - 6 weeks ago

Biogen to invest $2 billion more in North Carolina


Biogen: Investors Are Missing The Bigger Picture

Jun 22, 2025, 10:27 PM EDT - 2 months ago

Biogen: Investors Are Missing The Bigger Picture


Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:38 AM EDT - 4 months ago

Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript


StockAutoPro
StockAutoPro Sep. 7 at 11:45 PM
$BIIB: Buy target $138.67 Sell target $147.7 Potential growth seen in biotech sector due to increased investment in Alzheimer's research.
0 · Reply
forprofit12
forprofit12 Sep. 5 at 4:39 PM
$BIIB what a miserable PoS stock. Nothing moves this POS.
0 · Reply
iQuicky
iQuicky Sep. 5 at 1:12 PM
$BIIB good news coming?
0 · Reply
StockAutoPro
StockAutoPro Sep. 4 at 2:39 PM
$BIIB: Buy target $137.89 Sell target $146.88 Robust drug pipeline could signal potential growth for this leading biotech firm.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 4 at 11:17 AM
$CCCC $BIIB C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA
0 · Reply
JarvisFlow
JarvisFlow Sep. 4 at 10:30 AM
Needham has adjusted their stance on Biogen ( $BIIB ), setting the rating to Hold.
0 · Reply
Chingying
Chingying Sep. 3 at 6:57 PM
$BIIB This will be a big game changer if Rolling submission on fast track for once weekly subcutaneous Leqembi IQLIK autoinjector wins FDA approval to treat AZ disease from the start at home. IQLIK just won approval as maintenance dose on 08/29/2025.
1 · Reply
scientificway
scientificway Sep. 3 at 3:41 PM
$BIIB strong buy. PMN, Have cash and good result. Should be 0.5-14 turn 1000 to 2000
0 · Reply
iQuicky
iQuicky Sep. 3 at 1:55 PM
$BIIB what’s going on?
0 · Reply
GuruLulu
GuruLulu Sep. 3 at 1:51 PM
$BIIB very nice
0 · Reply
TradeMark79
TradeMark79 Sep. 3 at 1:46 PM
$BIIB …Nice….
0 · Reply
GuruLulu
GuruLulu Sep. 3 at 1:44 PM
$BIIB nice
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 3 at 1:39 PM
🎯 Target Hit (closed) 🏁 🏛️ $BIIB 💵 Entry: $138.2800 ✅ Exit: $141.3222 💰 P/L: +2.20% 📨 Signal was given on Sep 2, 2025. $SPY my $QQQ
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 3 at 1:36 PM
🎯 Target Hit (closed) 🏁 🏛️ $BIIB 💵 Entry: $138.2800 ✅ Exit: $141.3222 💰 P/L: +2.20% 📨 Signal was given on Sep 2, 2025. $SPY my $QQQ
0 · Reply
khmerxbxboi
khmerxbxboi Sep. 3 at 1:22 PM
$BIIB = $$$
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 3 at 2:40 AM
$BIIB Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Eisai and Biogen announced Eisai has begun a rolling sBLA submission to the FDA for LEQEMBI IQLIK, a subcutaneous autoinjector of lecanemab designed for early Alzheimer’s patients. The submission seeks approval for use as a once-weekly starting dose following the FDA’s Fast Track designation. LEQEMBI is already approved for Mild Cognitive Impairment and mild dementia stages of Alzheimer’s.
0 · Reply
Vin2k
Vin2k Sep. 2 at 2:57 PM
$BIIB Thought this would be up more
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 2 at 2:33 PM
🚨 New Signal ✅ 🏛️ $BIIB 🗓️ Sep 2, 2025 💵 Entry: $138.28 🎯 Suggested Target: $141.32 (+2.20%) (Optional)
0 · Reply
DenchDaddy
DenchDaddy Sep. 2 at 2:07 PM
$BIIB lets fucking get it US pharma had its ass kicked - let’s get some green
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 2 at 8:21 AM
$BIIB Biogen Inc. (BIIB)'s Alzheimer's Drug Leqembi Wins EU Nod, Now Approved in 48 Countries By Laiba Immad | September 02, 2025, 3:30 AM
0 · Reply
Irelandd
Irelandd Sep. 2 at 12:25 AM
$BIIB barely up a percent, what gives!!!
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 1 at 5:55 PM
$BIIB FDA Approves LEQEMBI IQLIK Weekly Subcutaneous Injection for Early Alzheimer’s Eisai and Biogen announced FDA approval of LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector for maintenance dosing in early Alzheimer’s patients. The 360 mg injection can be administered in ~15 seconds and offers an alternative to ongoing IV infusions. Patients completing 18 months of IV LEQEMBI treatment can now transition to the new autoinjector option.
0 · Reply